Cibus

San Diego, California Food & Agriculture Public

Cibus is an agricultural biotechnology company developing precision gene-edited plant traits using non-GMO gene editing technology (RTDS including TALEN and GRON). The company licenses gene-edited crop traits to seed companies for royalties, focusing on weed management, herbicide tolerance, and disease resistance in crops including rice, canola, and soybean. Following the June 2023 merger with Calyxt, Cibus operates as a public company (NASDAQ: CBUS) with over 1,000 issued or pending patents in gene editing for agriculture.

Public Company

Cibus is publicly traded

This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.

Overview

Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Founded

2001

Employees

100-250

Total Funding

$216M

3 rounds

Funding

Total raised $216M across 3 rounds

Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Last updated 05-08-2026

Latest Round

Type

Public Offering

Date

March 2024

Amount

$27.5M

Valuation

DateRoundAmount RaisedValuationLead Investors
March 2024 Public Offering $27.5M
June 1, 2023 Series F (Private Units) $118.5M
June 26, 2018 Series C $70M Fidelity Management and Research Company

Prominent Investors

Fidelity Management & Research acks.com Cormorant Asset Managemen Alexandria Venture Investments Fidelity Management and Research Company

Leadership

  • Peter Beetham

    Interim Chief Executive Officer, President & Chief Operating Officer

  • Rory Riggs

    Chairman of the Board of Directors

  • Greg Gocal

    Co-Founder & Chief Scientific Officer & EVP

  • James Radtke

    SVP, Product Development

  • Noel Sauer

    SVP, Research

  • Rosa Cheuk Kim

    SVP, Legal

Cibus Investment FAQ

Cibus FAQ

Cibus merged with Calyxt via SPAC transaction, with combined company beginning public trading on NASDAQ Capital Market under ticker CBUS on June 1, 2023. The company remains public and filed 10-K annual report in March 2025.

Cibus shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.

Cibus raised $216M across 3 disclosed funding rounds prior to its public listing.

Cibus was founded by Greg Gocal in 2001.

Cibus is headquartered in San Diego, California.

Access live market data

Sign Up

Data collected with AI, which can make mistakes. Please double-check this information.